Sunshine Biopharma (SBFM) Total Debt (2017 - 2021)

Sunshine Biopharma has reported Total Debt for 5 years, with the latest figure at $1.9 million in Q4 2021.

• For the quarter ending Q4 2021, Total Debt rose 100.21% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2021 stood at $1.9 million (up 100.21% YoY), and the FY2021 full-year result was $1.9 million, up 100.21% from the prior year.
• Total Debt for Q4 2021 stood at $1.9 million, down from $3.2 million in the prior quarter.
• The five-year high for Total Debt was $3.2 million in Q3 2021, with the low at $27541.0 in Q3 2019.
• Historically, Total Debt has averaged $900860.2 across 5 years, with a median of $349383.0 in 2019.
• Annual changes were most pronounced in 2019 — Total Debt tumbled 91.0% — and 2021, when it soared 3148.59%.
• Sunshine Biopharma's Total Debt stood at $79710.0 in 2017, then soared by 289.81% to $310718.0 in 2018, then slumped by 91.14% to $27541.0 in 2019, then jumped by 3345.79% to $949006.0 in 2020, then surged by 100.21% to $1.9 million in 2021.
• The last three Total Debt figures came in at $1.9 million (Q4 2021), $3.2 million (Q3 2021), and $2.1 million (Q2 2021), per Business Quant data.